A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The findings, published in Cell Host & Microbe, may represent a breakthrough strategy for treating West Nile Virus after virus invasion of the brain and the central nervous system, noted senior author Priti Kumar, M.D., associate professor of infectious disease at Yale School of Medicine.
There are no approved vaccines or effective therapies for West Nile Virus disease, a mosquito-borne condition. While many infected individuals have no symptoms, others — particularly the very young and older adults — can develop severe neurological problems and even die from the disease. The sporadic nature of the disease makes it exceedingly difficult for testing and implementing vaccines, said Kumar.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small “interfering” RNA molecule developed in her lab. The RNA acts against multiple mosquito-borne flaviviruses. To direct the RNA to infected cells, they packaged it in a peptide derived from the rabies virus, which is able to enter nerve cells. The final step was to the deliver the therapy through the nose where it could bypass natural barriers protecting the brain.
With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells. The treated mice had a 90% survival rate a few days after infection compared to mice treated with placebo. Significantly, noted the researchers, in the surviving mice, the immune system cleared the virus throughout the body, and also enabled long-term protection against future exposure.
The researchers concluded that the treatment offers both a promising late-stage therapy and lifelong immunity. It “prevents pathology in the brain and gives the mice a chance to develop a robust immune response,” said Kumar.
While the anatomy of the murine nose differs from that of humans, the researchers plan to study the therapy further with the hope it will be broadly applicable. “In translation, it should be an effective strategy for people,” she said.
If that is the case, the intranasal RNA therapy could theoretically be developed for treatment of other mosquito-borne diseases, such as St. Louis encephalitis, Japanese encephalitis, and perhaps Zika, the researchers noted.
The Latest on: RNA therapy
via Google News
The Latest on: RNA therapy
- Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver diseaseon May 11, 2020 at 12:43 pm
LNPs have been specifically tested for hepatocyte delivery of siRNA molecules, since the liver is a well-perfused organ with a fenestrated endothelium. On the other hand, LNPs are known to interact ...
- COVID-19: Rescue by transcriptional inhibitionon May 11, 2020 at 12:41 pm
The National Institutes of Health (NIH) recently disclosed preliminary results from their highly anticipated clinical study with the viral specific transcriptional inhibitor Remdesivir for the ...
- Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Updateon May 11, 2020 at 4:30 am
Wave to host investor conference call and webcast at 8:30 a.m. ET today. CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Ltd. (Nasdaq: WVE), a clinical-stage ...
- Anastasia Khvorova elected director of the American Society of Gene and Cell Therapyon May 10, 2020 at 9:03 pm
UMass Medical School RNA therapeutics expert Anastasia Khvorova, PhD, has been elected by the membership of the American Society of Gene and Cell Therapy to a three-year term as ...
- Avalon GloboCare advancing immune cell therapy to treat blood cancers using FLASH-CAR technologyon May 8, 2020 at 7:07 am
CAR platform can be used to create personalized cell therapy from a patient’s own cells, as well as off-the-shelf cell therapy from a universal donor ...
- Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 geneon May 5, 2020 at 2:26 am
We report on the validation of a mitochondrial gene therapeutic strategy using fibroblasts from a Leigh syndrome patient by the mitochondrial delivery of therapeutic mRNA. The treatment involves ...
- Vir, Alnylam plan human trials by year-end for potential COVID-19 therapyon May 4, 2020 at 1:46 pm
Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmake ...
- Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year endon May 4, 2020 at 5:27 am
Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday.
- RNA Sequencing Finds Immune System Clues Long Before Patients Develop Multiple Myelomaon May 1, 2020 at 2:49 pm
New research could make it easier to find out which patients are mostly likely to go on to develop multiple myeloma. The findings could have implications for therapeutic interventions.
via Bing News